UNITÉ DE RECHERCHE Centre de Recherche en Cancérologie de Marseille

Transcription

1 UNITÉ DE RECHERCHE Centre de Recherche en Cancérologie de Marseille DIRECTEUR : BORG Jean-Paul ADRESSE : Institut Paoli Calmettes 27 Bd Lei Roure BP Marseille cedex 09 TELEPHONE : COURRIEL : jean-paul.borg@inserm.fr RATTACHEMENTS : AMU INSERM CNRS IPC POLES HOSPITALIERS : 3 - Imagerie Médicale (Intersites) 5 - Anapath-Digestif-Onco-Uro-Endocrinologie (Nord) ECOLE DOCTORALE : Sciences de la Vie et de la Santé (ED 062) DISCIPLINES D APPARTENANCES : DS 5 - Biologie, médecine, santé SPECIALITÉS : Oncologie/Immunologie GESTIONNAIRES DE L UNITÉ : DUVIVIER Laurence EFFECTIFS Enseignants-Chercheurs : 14 Chercheurs EPST : 49 Autres Chercheurs : 36 IATOS/ITA : 66 Autres IATOS/ITA : 23 Doctorants : 54 Unité de Recherche. Centre de Recherche en Cancérologie de Marseille 1/23

2 PERSONNELS IMPLIQUÉS DANS LA RECHERCHE Nom Prénom statut Téléphone Acquaviva Laurent CR Acquaviva Claire thèse Acunzo Julie postdoc Adélaïde José Tech IPC Afrache Hassnae thèse Agnelli Lauren IE INSERM Andrieu Claudia thèse Aouar Besma thèse Aragnol Denise PU Arbiol Christine AI INSERM Arnoulet Christine PH Audebert Stéphane IR INSERM ou Audry Julien thèse Aurrand-Lions Michel CR Baccini Michel TCN INSERM Badache Ali DR Bailly Éric CR Bapin Luc TCN INSERM Barbarat Bernadette THQ IPC Bardin Florence AI INSERM Baron-Gaillard Carole postdoc Barthet Marc PU PH Basse Marie jeanne AI INSERM Baty Daniel DR Baudelet Émilie AI INSERM Baylot Virginie thèse Benseddik Khedidja thèse Benyamine Audrey thèse Bernard Stéphanie IE INSERM Berthezene Patrice IEH INSERM Bertucci François PUPH et poste 4779 Betzi Stéphane postdoc Bidaut Ghislain IR2 INSERM Birg Françoise DR Birnbaum Daniel DR ou Blaise Didier MD PU-PH Bodin Jérome IE INSERM Bonacci Thomas Thèse Borg Jean-Paul PU PH Borge Laurence AI INSERM Bourdely Pierre thèse Bourgeas Raphaël thèse Boutchama Henri TCN INSERM ou Brecqueville Mandy Thèse Poste 4508 Brisson Lydie Thèse Brunel Jean michel CR Cabaud Olivier IE INSERM Calmels Boris PH Camoin Luc IR INSERM Carbuccia Nadine AI INSERM Carrier Alice CR Unité de Recherche. Centre de Recherche en Cancérologie de Marseille 2/23

3 Castellano Rémy IR IPC Celis-Gutierrez Javier thèse Cervera Nathalie Tech IPC Chabannon Christian PU Chaffanet Max Cadre IPC Chames Patrick CR Charafe-jauffret Emmanuelle PUPH Charifi Férose postdoc Chetaille Bruno MD PH Chetrit Bernard IE INSERM Chevrier Véronique IR1 INSERM Churikov Dmitri postdoc Collette Yves DR Combes Sébastien MCU Coppin Émilie thèse Corda Yves CR Cornen Stéphanie thèse Poste 4508 Coulier François CR Coulon Stéphane CR Daou Pascale thèse Daulat Avais postdoc David Guido thèse de la Roche Saint André Christophe CR De Sepulveda Paulo CR Dehe Pierre-Marie postdoc Derviaux Carine thèse Devillier Raynier thèse Poste 4508 Drivet Elsa thèse Drogat Julie postdoc Dubois Kenny IE INSERM Dubreuil Patrice DR Duprez Estelle DR Dusetti Nelson DR Duvivier Laurence AI INSERM Fauriat Cyril CR Ferrier Valérie Cadre IPC Finetti Pascal Tech IPC Florentin Jonathan thèse Fuchs Robert DRCE Fujii Shingo CR Gaillard Pierre-Henri CR Garcia Julie thèse Garcia Maria Noé thèse Garcia Maxime thèse Garcia Stéphane thèse Garzino Patrick TCE INSERM Gayet Odile IE INSERM Géli Vincent DR Gelsi-Boyer Véronique MCU Geneix Jeannine Tech IPC Georges Coralie AI INSERM Ghossoub Rania Post-Doc Gianardi Fabrice TN INSERM Gibier Patrick AI INSERM Ginestier Christophe CR Gonçalvès Anthony PH Unité de Recherche. Centre de Recherche en Cancérologie de Marseille 3/23

4 Gondois-Rey Françoise IR2 INSERM Goubard Armelle THQ IPC Granjeaud Samuel IR1 INSERM Grasso Daniel thèse Guenneau-Puvirajesinghe Tania Post-Doc Guervilly Jean-Hugues postdoc Guillaumond Fabienne postdoc Guille Arnaud IE INSERM Hamidi Tewfik thèse Hammam Kahina thèse Hamon Veronique postdoc Hardy Julien thèse Hirsch Ivan DR Imbert Anne-Marie THQ IPC Iovanna Juan DR Isnardon Daniel IR IPC Isogawa Asako IR CNRS Josselin Emmanuelle AI INSERM Jourquin Frédéric IE CNRS Just-Landi Sylvaine Tech IPC Ka Mignane thèse Karaki Sara Thèse Kashyap Rudra thèse Katsogiannou Maria postdoc Kerfelec Brigitte CR Koubi Myriam thèse Laloum Laurence TCN INSERM Launay Simon thèse Lavaut Marie-Noëlle IE AMU Le Suong thèse Le Roy Aude thèse Leca Julie thèse Lecocq Éric TCE INSERM Lembo Frédérique THQ IPC Letard Sébastien Tech AMU Letessier Anne CR2 Poste 4508 Lhoumeau Anne-Catherine thèse Lissitzky Jean-Claude CR Liu Xiaoxuan postdoc Livrati Philippe Tech IPC Llorente Bertrand CR Lombard Benjamin IE INSERM Loncle Céline IE INSERM Lopez Marc IR INSERM Lopez Sophie IR INSERM Luciano Pierre CR Malenfant Carine Tech INSERM Mallet Françoise Tech IPC Maneville Stéphanie thèse Marchetto Sylvie IR2 INSERM Martinez Sébastien thèse Mezil Lynda thèse Mille Delphine TCN INSERM Modesti Mauro DR Moldawan Yvonne ATP INSERM Monges Geneviève PH Unité de Recherche. Centre de Recherche en Cancérologie de Marseille 4/23

5 Morazzani Betty TCE INSERM Morelli Xavier CR Morin Stéphanie thèse Mosca Cyndie IE INSERM Mozziconacci Marie-Joëlle PH Murati Anne PH Naiman Karel postdoc Négrel Aurélie IE INSERM Nevoltris Damien thèse Nigri Jérémy Tech IPC Nunès Jacques DR Olivares Orianne thèse Olive Daniel PU PH Olivares Orianne thèse Olivier Bruno ATP2 IPC Orlanducci Florence Tech IPC Orsoni Jean-Christophe TCE INSERM Pages Vincent CR Palud Adeline Chercheur contractuel CNRS Pasero Christine postdoc Pastor Sonia AI INSERM Peltier Julien thèse Peuget Sylvain thèse Philippin Gaëlle IE CNRS Pinet Isabelle TCE CNRS Platet Nadine IR CNRS Poinsignon Catherine Chercheur contractuel CNRS (CEFIC) Pophillat Matthieu IE INSERM Pouyet Laurent postdoc Prébet Thomas PH Receveur-Bréchot Véronique DR Restouin Audrey THQ Rey Jérôme thèse Rocchi Palma CR Rochas Caroline IE INSERM Roche Philippe CR Rosnet Olivier CR Roubin Régine CR Roux Claude IE INSERM Rovere Julie Tech IPC Sabatier Renaud med Salaun Danièle AI INSERM Salvador Marion thèse Santoni Marie-Josée CR Sari Karim TN INSERM Scaglione Sarah AI INSERM Sebbagh Michaël CR Secq Véronique med Seillier Marion IE INSERM Simon Marie-Noëlle CR Skrobuk Paulina postdoc Sonongbua Ying thèse Unité de Recherche. Centre de Recherche en Cancérologie de Marseille 5/23

6 Soubeyran Philippe CR Soucie Erinn postdoc Spoto Patricia TN INSERM Stahl Olivier THQ IPC Stranska Ružena postdoc Taieb David PU PH Takedachi Arato postdoc Tardivel-Lacombe Joël IE1D INSERM Termine Elise IE2 INSERM Tiberi Guillaume IE INSERM Toiron Yves Technicien IPC Tomasini Richard CR Torres Martine AJT CNRS Tournaire Roselyne MCU Traore Wilfried thèse Turini Marc thèse Van Hiel Boris thèse Vasseur Sophie CR Verdier-Pinard Pascal CR Verdiglione Noémie IE INSERM Vey Norbert PH Viens Patrice PUPH Vincent-Fabert Christelle postdoc Vita Marina postdoc Wicinski Julien Tech IPC Xerri Luc PU PH Yagi Yoshihiko IE INSERM Yahiaoui Imène thèse Zhang Xu thèse Zimmermann Pascale DR EQUIPE : E1 - Molecular Oncology RESPONSABLE : BIRBAUM Daniel EQUIPES DE RECHERCHE et THEMATIQUES EQUIPE : E2 - Cell Polarity, Cell Signaling and Cancer RESPONSABLE : BORG Jean-Paul EQUIPE : E3 - Signalling, haematopoiesis and mechanisms of oncogenesis RESPONSABLE : DUBREUIL Patrice EQUIPE : E4 - Tumor Cell Motility RESPONSABLE : BADACHE Ali EQUIPE : E5 - Adhésion Molecules in Tumour/host Interactions RESPONSABLE : AURRAND-LIONS Michel EQUIPE : E6 - Epigenetic control of normal and pathological hematopiesis RESPONSABLE : DUPREZ Estelle EQUIPE : E7 - PDZ scaffold proteins and phosphoinoslitides in cell signalling and oncogenesis RESPONSABLE : ZIMMERMANN Pascale EQUIPE : E8 - Cell stress RESPONSABLE : IOVANNA Juan Unité de Recherche. Centre de Recherche en Cancérologie de Marseille 6/23

7 EQUIPE : E9 - Tolerance of lesions in DNA RESPONSABLE : FUCHS Robert EQUIPE : E10 - Tolerance, Senescence and DNA damage RESPONSABLE : GELI Vincent EQUIPE : E11 - Mechanisms of DNA double-strand break repair system : homologous recombination and NHEJ RESPONSABLE : MODESTI Mauro EQUIPE : E12 - Control of structure-specific endonucleases and genome stability RESPONSABLE : GAILLARD Pierre-Henri EQUIPE : E13 - Genome dynamics and recombination RESPONSABLE : Llorente Bertrand EQUIPE : E14 - Immunity & Cancer RESPONSABLE : OLIVE Daniel EQUIPE : E15 - Fundamental & Therapeutic Chemical Biology RESPONSABLE : COLLETTE Yves EQUIPE : E16 - Antibody Therapeutics & Immunotargeting RESPONSABLE : BATY Daniel PERSONNELS PAR EQUIPE DE RECHERCHE EQUIPE : E1 - Molecular Oncology RESPONSABLE : BIRBAUM Daniel Acquaviva Acunzo Adélaïde Andrieu Baylot Bertucci Birnbaum Brecqueville Cabaud Carbuccia Cervera Chaffanet Charafe-jauffret Chevrier Cornen Devillier Finetti Gelsi-Boyer Geneix Ginestier Guille Josselin Karaki Katsogiannou Launay Letessier Liu Lopez Claire Julie José Claudia Virginie François Daniel Mandy Olivier Nadine Nathalie Max Emmanuelle Véronique Stéphanie Raynier Pascal Véronique Jeannine Christophe Arnaud Emmanuelle Sara Maria Simon Anne Xiaoxuan Marc Unité de Recherche. Centre de Recherche en Cancérologie de Marseille 7/23

8 Mezil Monges Mozziconacci Murati Rocchi Rosnet Roubin Sabatier Salvador Taieb Viens Wicinski Lynda Geneviève Marie-Joëlle Anne Palma Olivier Régine Renaud Marion David Patrice Julien EQUIPE : E2 - Cell Polarity, Cell Signaling and Cancer RESPONSABLE : BORG Jean-Paul Bailly Borg Daulat Gonçalvès Guenneau-Puvirajesinghe Lhoumeau Marchetto Martinez Prébet Santoni Sebbagh Toiron Traore Audebert Baudelet Camoin Peltier Pophillat Éric Jean-Paul Avais Anthony Tania Anne-Catherine Sylvie Sébastien Thomas Marie-Josée Michaël Yves Wilfried Stéphane Émilie Luc Julien Matthieu EQUIPE : E3 - Signalling, haematopoiesis and mechanisms of oncogenesis RESPONSABLE : DUBREUIL Patrice De Sepulveda Dubreuil Georges Hammam Lecocq Letard Lopez Mosca Soucie Vita Paulo Patrice Coralie Kahina Éric Sébastien Sophie Cyndie Erinn Marina EQUIPE : E4 - Tumor Cell Motility RESPONSABLE : BADACHE Ali Badache Benseddik Daou Salaun Verdier-Pinard Ali Khedidja Pascale Danièle Pascal Unité de Recherche. Centre de Recherche en Cancérologie de Marseille 8/23

9 EQUIPE : E5 - Adhésion Molecules in Tumour/host Interactions RESPONSABLE : AURRAND-LIONS Michel Aurrand-Lions Bardin Lissitzky Michel Florence Jean-Claude EQUIPE : E6 - Epigenetic control of normal and pathological hematopiesis RESPONSABLE : DUPREZ Estelle Calmels Chabannon Duprez Imbert Koubi Platet Tiberi Verdiglione Vincent-Fabert Boris Christian Estelle Anne-Marie Myriam Nadine Guillaume Noémie Christelle EQUIPE : E7 - PDZ scaffold proteins and phosphoinoslitides in cell signalling and oncogenesis RESPONSABLE : ZIMMERMANN Pascale Baron-Gaillard David Ghossoub Kashyap Lembo Van Hiel Zimmermann Carole Guido Rania Rudra Frédérique Boris Pascale EQUIPE : E8 - Cell stress RESPONSABLE : IOVANNA Juan Barthet Berthezene Bonacci Borge Brisson Carrier Dusetti Garcia Garcia Garcia Gayet Gianardi Grasso Guillaumond Hamidi Iovanna Lavaut Leca Loncle Nigri Olivares Olivier Marc Patrice Thomas Laurence Lydie Alice Nelson Julie Maria Noé Stéphane Odile Fabrice Daniel Fabienne Tewfik Juan Marie-Noëlle Julie Céline Jérémy Orianne Bruno Unité de Recherche. Centre de Recherche en Cancérologie de Marseille 9/23

10 Peuget Sari Secq Seillier Skrobuk Soubeyran Spoto Tardivel-Lacombe Tomasini Tournaire Vasseur Sylvain Karim Véronique Marion Paulina Philippe Patricia Joël Richard Roselyne Sophie EQUIPE : E9 - Tolerance of lesions in DNA RESPONSABLE : FUCHS Robert FUCHS Robert FUJII Shingo ISOGAWA Asako PAGES Vincent PALUD Adeline PHILIPPIN Gaëlle POINSIGNON Catherine DR INSERM IR CNRS IR CNRS CR CNRS Chercheur contractuel CNRS IE CNRS Chercheur contractuel CNRS (CEFIC) EQUIPE : E10 - Tolemère, Senescence and DNA damage RESPONSABLE : GELI Vincent Acquaviva Aragnol Audry Charifi Churikov Corda Coulon de la Roche Saint André Drogat Géli Hardy Jourquin Luciano Simon Torres Laurent Denise Julien Férose Dmitri Yves Stéphane Christophe Julie Vincent Julien Frédéric Pierre Marie-Noëlle Martine EQUIPE : E11 - Mechanisms of DNA double-strand break repair system : homologous recombination and NHEJ RESPONSABLE : MODESTI Mauro Bernard Bodin Modesti Négrel Stéphanie Jérome Mauro Aurélie EQUIPE : E12 - Control of structure-specific endonucleases and genome stability RESPONSABLE : GAILLARD Pierre-Henri Dehe Gaillard Guervilly Scaglione Takedachi Pierre-Marie Pierre-Henri Jean-Hugues Sarah Arato Unité de Recherche. Centre de Recherche en Cancérologie de Marseille 10/23

11 EQUIPE : E13 - Genome dynamics and recombination RESPONSABLE : Llorente Bertrand Arbiol Dubois Llorente Christine Kenny Bertrand EQUIPE : E14 - Immunity & Cancer RESPONSABLE : OLIVE Daniel Afrache Aouar Arnoulet Barbarat Benyamine Blaise Bourdely Celis-Gutierrez Chetaille Coppin Fauriat Florentin Gondois-Rey Hirsch Just-Landi Ka Le Le Roy Livrati Mallet Morin Nunès Olive Orlanducci Pasero Pastor Rey Rochas Sonongbua Stranska Vey Xerri Yahiaoui Hassnae Besma Christine Bernadette Audrey Didier Pierre Javier Bruno Émilie Cyril Jonathan Françoise Ivan Sylvaine Mignane Suong Aude Philippe Françoise Stéphanie Jacques Daniel Florence Christine Sonia Jérôme Caroline Ying Ružena Norbert Luc Imène EQUIPE : E15 - Fundamental & Therapeutic Chemical Biology RESPONSABLE : COLLETTE Yves MORELLI Xavier Basse Betzi Bourgeas Brunel Castellano Chetrit Collette Combes Derviaux Marie jeanne Stéphane Raphaël Jean michel Rémy Bernard Yves Sébastien Carine Unité de Recherche. Centre de Recherche en Cancérologie de Marseille 11/23

12 Drivet Goubard Hamon Maneville Morazzani Morelli Pouyet Receveur-Bréchot Restouin Roche Zhang Elsa Armelle Veronique Stéphanie Betty Xavier Laurent Véronique Audrey Philippe Xu EQUIPE : E16 - Antibody Therapeutics & Immunotargeting RESPONSABLE : BATY Daniel Agnelli Baty Chames Kerfelec Lombard Nevoltris Rozan Termine Turini Lauren Daniel Patrick Brigitte Benjamin Damien Caroline Elise Marc EQUIPE : E17 - BIOINFORMATIQUE INTEGRATIVE Bidaut Ghislain Garcia Maxime Granjeaud Samuel EQUIPE : E18 - SERVICES COMMUNS Baccini Michel Bapin Luc Birg Françoise Boutchama Henri Coulier François Granjeaud Samuel Garzino Patrick Gibier Patrick Isnardon Daniel Laloum Laurence Mille Delphine Moldawan Yvonne Orsoni Jean-Christophe Pinet Isabelle Roux Claude Rovere Julie Unité de Recherche. Centre de Recherche en Cancérologie de Marseille 12/23

13 PUBLICATIONS ANNÉES 2010 et Acquaviva,C., Gelsi-Boyer, V., and Birnbaum, D. Myelodysplastic syndromes: lost between two states? Leukemia. 2010;24: Addou-Klouche,L., Adelaide, J., Finetti, P., Cervera, N., Ferrari, A., Bekhouche, I., Sircoulomb, F., Sotiriou, C., Viens, P., Moulessehoul, S., Bertucci, F., Birnbaum, D., and Chaffanet, M. Loss, mutation and deregulation of L3MBTL4 in breast cancers. Molecular Cancer. 2010;9: Adelaide,J., Gelsi-Boyer, V., Rocquain, J., Carbuccia, N., Birnbaum, D. J., Finetti, P., Bertucci, F., Mozziconacci, M. J., Vey, N., Birnbaum, D., and Chaffanet, M. Gain of CBL-interacting protein, a possible alternative to CBL mutations in myeloid malignancies. Leukemia. 2010;24: Bertucci,F., Finetti, P., Sabatier, R., and Birnbaum, D. The CINSARC signature: prognostic and predictive of response to chemotherapy? Cell Cycle. 2010;9: Bertucci,F., Finetti, P., Birnbaum, D., and Viens, P. Gene expression profiling of inflammatory breast cancer. Cancer. 2010;116: Bidaut, G. Interpreting and Comparing Clustering Experiments Through Graph Visualization and Ontology Statistical Enrichment with the ClutrFree Package. Biomedical Informatics for Cancer Research. [19], Ref Type: Book Chapter 7. Birnbaum,D.J., Sabatier, R., Mamessier, E., Birnbaum, D., and Bertucci, F. Une forme «ariditaire» du cancer de l'ovaire. M/S Medecine Sciences. 2010;26: Carbuccia,N., Trouplin, V., Gelsi-Boyer, V., Murati, A., Rocquain, J., Adelaide, J., Olschwang, S., Xerri, L., Vey, N., Chaffanet, M., Birnbaum, D., and Mozziconacci, M. J. Mutual exclusion of ASXL1 and NPM1 mutations in a series of acute myeloid leukemias. Leukemia. 2010;24: Chabannon,C., Honstettre, A., Daufresne, L. M., Martin, P. M., Bonnetaud, C., Birtwisle- Peyrottes, I., Romain, S., Achache, K., Mery, O., Bordonne, O., Ducord, C., Jacotot, L., Vaglio, P., d'arnoux, C., Figarella-Branger, D., Hofman, P., Borg, J. P., and Atger, V. Publication of biological samples collections catalogues by tumor banks. La publication de catalogues de collections d'échantillons biologiques par les tumorothèques. Bulletin du Cancer. 2010;97: Chapiro,E., Russell, L., Lainey, E., Kaltenbach, S., Ragu, C., Della-Valle, V., Hanssens, K., Macintyre, E. A., Radford-Weiss, I., Delabesse, E., Cave, H., Mercher, T., Harrison, C. J., Nguyen- Khac, F., Dubreuil, P., and Bernard, O. A. Activating mutation in the TSLPR gene in B-cell precursor lymphoblastic leukemia. Leukemia. 2010;24: Charafe-Jauffret,E., Ginestier, C., Iovino, F., Tarpin, C., Diebel, M., Esterni, B., Houvenaeghel, G., Extra, J. M., Bertucci, F., Jacquemier, J., Xerri, L., Dontu, G., Stassi, G., Xiao, Y., Barsky, S. H., Birnbaum, D., Viens, P., and Wicha, M. S. Aldehyde Dehydrogenase 1-Positive Cancer Stem Cells Mediate Metastasis and Poor Clinical Outcome in Inflammatory Breast Cancer. Clinical Cancer Research. 2010;16: Charafe-Jauffret,E., Ginestier, C., and Birnbaum, D. Cancer stem cells: Just sign here! Cell Cycle. 2010;9: Coursindel,T., Restouin, A., Dewynter, G., Martinez, J., Collette, Y., and Parrot, I. Stereoselective ring contraction of 2,5-diketopiperazines: an innovative approach to the synthesis of promising bioactive 5-membered scaffolds. Bioorganic Chemistry. 2010;38: De Lavallade,H., Finetti, P., Carbuccia, N., Khorashad, J. S., Charbonnier, A., Foroni, L., Apperley, J. F., Vey, N., Bertucci, F., Birnbaum, D., and Mozziconacci, M. J. A gene expression signature of primary resistance to imatinib in chronic myeloid leukemia. Leukemia Research. 2010;34: Unité de Recherche. Centre de Recherche en Cancérologie de Marseille 13/23

14 15. Derre,L., Rivals, J. P., Jandus, C., Pastor, S., Rimoldi, D., Romero, P., Michielin, O., Olive, D., and Speiser, D. E. BTLA mediates inhibition of human tumor-specific CD8+ T cells that can be partially reversed by vaccination. Journal of Clinical Investigation. 2010;120: Fei,F., Kweon, S. M., Haataja, L., De Sepulveda, P., Groffen, J., and Heisterkamp, N. The Fer tyrosine kinase regulates interactions of Rho GDP-Dissociation Inhibitor a with the small GTPase Rac. BMC Biochemistry. 2010;11: Fournier,G., Garrido-Urbani, S., Reymond, N., and Lopez, M. Nectin and nectin-like molecules as markers, actors and targets in cancer. M/S Medecine Sciences. 2010;26: Gelsi-Boyer,V., Trouplin, V., Roquain, J., Adelaide, J., Carbuccia, N., Esterni, B., Finetti, P., Murati, A., Arnoulet, C., Zerazhi, H., Fezoui, H., Tadrist, Z., Nezri, M., Chaffanet, M., Mozziconacci, M. J., Vey, N., and Birnbaum, D. ASXL1 mutation is associated with poor prognosis and acute transformation in chronic myelomonocytic leukaemia. British Journal of Haematology. 2010;151: Ghiotto,M., Gauthier, L., Serriari, N., Pastor, S., Truneh, A., Nunes, J. A., and Olive, D. PD-L1 and PD-L2 differ in their molecular mechanisms of interaction with PD-1. International Immunology. 2010;22: Gilabert,M., Audebert, S., Viens, P., Borg, J. P., Bertucci, F., and Goncalves, A. Proteomics and breast cancer: a search for novel diagnostic and theragnostic biomarkers. Bulletin du Cancer. 2010;97: Ginestier,C., Charafe-Jauffret, E., and Birnbaum, D. Targeting breast cancer stem cells: fishing season open! Breast Cancer Research. 2010;12: Ginestier,C., Liu, S., Diebel, M. E., Korkaya, H., Luo, M., Brown, M., Wicinski, J., Cabaud, O., Charafe-Jauffret, E., Birnbaum, D., Guan, J. L., Dontu, G., and Wicha, M. S. CXCR1 blockade selectively targets human breast cancer stem cells in vitro and in xenografts. Journal of Clinical Investigation. 2010;120: Giusiano,S., Secq, V., Carcopino, X., Carpentier, S., Andrac, L., Lavaut, M. N., Allasia, C., Bonnier, P., Iovanna, J. L., Garcia, S., Boubli, L., Birnbaum, D., and Charpin, C. Immunohistochemical profiling of node negative breast carcinomas allows prediction of metastatic risk. International Journal of Oncology. 2010;36: Guittard,G., Mortier, E., Tronchere, H., Firaguay, G., Gerard, A., Zimmermann, P., Payrastre, B., and Nunes, J. A. Evidence for a positive role of PtdIns5P in T-cell signal transduction pathways. FEBS Letters. 2010;584: Hahn,K.A., Legendre, A. M., Shaw, N. G., Phillips, B., Ogilvie, G. K., Prescott, D. M., Atwater, S. W., Carreras, J. K., Lana, S. E., Ladue, T., Rusk, A., Kinet, J. P., Dubreuil, P., Moussy, A., and Hermine, O. Evaluation of 12- and 24-month survival rates after treatment with masitinib in dogs with nonresectable mast cell tumors. American Journal of Veterinary Research. 2010;71: Hirsch,I., Caux, C., Hasan, U., Bendriss-Vermare, N., and Olive, D. Impaired Toll-like receptor 7 and 9 signaling: from chronic viral infections to cancer. Trends in Immunology. 2010;31: Hudson,T., Anderson, W., Aretz, A., Bell, C., Bernabe, R., Bhan, M., Calvo, F., Eerola, I., Gerhard, D., Guttmacher, A., Guyer, M., Hemsley, F., Jennings, J., Kerr, D., Klatt, P., Kolar, P., Lane, D., Laplace, F., Nettekoven, G., Ozenberger, B., Peterson, J., Rao, T., Remacle, J., Schafer, A., Shibata, T., Stratton, M., Watanabe, K., Yuen, M., Cambon-Thomsen, A., Dressler, L., Joly, Y., Kennedy, K., Parker, M., Romeo-Casabona, C., Wallace, S., Wiesner, G., Zeps, N., Biankin, A., Chabannon, C., de Alava, E., Ferguson, M., Geary, P., Hayes, N., Johns, A., Kasprzyk, A., Nakagawa, H., Piris, M., van de Vijver, M., Aburatani, H., Bayes, M., Bowtell, D., Campbell, P., Hirst, M., Lopez-Otin, C., Marra, M., Ning, Z., Puente, X., Ruan, Y., Stunnenberg, H., Swerdlow, H., Velculescu, V., Xue, H., Yang, L., Spellman, P., Bader, G., Boutros, P., Flicek, P., Getz, G., Guigo, R., Guo, G., Haussler, D., Hubbard, T., Jiang, T., Jones, S., Li, Q., Lopez-Bigas, N., Luo, R., Muthuswamy, L., Ouellette, F., Pearson, J., Quesada, V., Raphael, B., Sander, C., Stein, L., Stuart, J., Teague, J., Totoki, Y., Tsunoda, T., Valencia, A., Wheeler, D., Wu, H., Zhao, S., Zhou, G., Unité de Recherche. Centre de Recherche en Cancérologie de Marseille 14/23

15 Lathrop, M., Axton, M., Dyke, S., Gunter, C., McPherson, J., Miller, L., Zhang, J., Haider, S., Wang, J., Yung, C., Cross, A., Liang, Y., Gnaneshan, S., Guberman, J., Hsu, J., Bobrow, M., Chalmers, D., Hasel, K., Kaan, T., Knoppers, B., Lowrance, W., Masui, T., Nicolas, P., Rial-Sebbag, E., Rodriguez, L., Vergely, C., Grimmond, S., Bowtell, D., Cloonan, N., defazio, A., Eshleman, J., Etemadmoghadam, D., Gardiner, B., Kench, J., Scarpa, A., Sutherland, R., Tempero, M., Waddell, N., Wilson, P., Gallinger, S., Tsao Ming, S., Shaw, P., Petersen, G., Mukhopadhyay, D., Chin, L., DePinho, R., Thayer, S., Shazand, K., Beck, T., Sam, M., Timms, L., Ballin, V., Ji, J., Zhang, X., Chen, F., Hu, X., Yang, Q., Tian, G., Zhang, L., Xing, X., Li, X., Zhu, Z., Yu, Y., Yu, J., Yang, H., Tost, J., Brennan, P., Holcatova, I., Zaridze, D., Brazma, A., Egevad, L., Prokhortchouk, E., Banks, R., Uhlen, M., Viksna, J., Ponten, F., Skryabin, K., Futreal, A., Birney, E., Caldas, C., Reis-Filho, J., Richardson, A., Sotiriou, C., Birnbaum, D., Blanche, H., Boucher, P., Boyault, S., Jacquemier, J., Pauporte, I., Pivot, X., Vincent-Salomon, A., Tabone, E., Theillet, C., Treilleux, I., Bioulac-Sage, P., Clement, B., Decaens, T., Degos, F., Franco, D., Gut, I., Gut, M., Heath, S., Samuel, D., Thomas, G., Zucman-Rossi, J., Eils, R., Brors, B., Korbel, J., Korshunov, A., Landgraf, P., Lehrach, H., Pfister, S., Radlwimmer, B., Reifenberger, G., Taylor, M., von Kalle, C., Majumder, P., Sarin, R., Pederzoli, P., Lawlor, R., Delledonne, M., Bardelli, A., Gress, T., Klimstra, D., Zamboni, G., Nakamura, Y., Kusuda, J., Miyano, S., Kato, K., Fujimoto, A., Yoshida, T., Campo, E., Estivill, X., de Sanjose, S., Montserrat, E., Gonzalez-Diaz, M., Himmelbaue, H., Bea, S., Aparicio, S., Borg, A., Borresen-Dale, A. L., Foekens, J., van't Veer, L., Easton, D., Martin, S., Compton, C., Lander, E., Penny, R., Shaw, K., Speed, T., Vockley, J., Lichter, P., Barker, A., Burke, W., Collins, F., Green, A., Hamilton, S., Kallioniemi, O., Ley, T., Liu, E., and Lu, Y. International network of cancer genome projects. Nature. 2010;464: Humbert,M., Casteran, N., Letard, S., Hanssens, K., Iovanna, J., Finetti, P., Bertucci, F., Bader, T., Mansfield, C. D., Moussy, A., Hermine, O., and Dubreuil, P. Masitinib combined with standard gemcitabine chemotherapy: in vitro and in vivo studies in human pancreatic tumour cell lines and ectopic mouse model. PLoS ONE. 2010;5:e Kosmider,O., Gelsi-Boyer, V., Slama, L., Dreyfus, F., Beyne-Rauzy, O., Quesnel, B., Hunault- Berger, M., Slama, B., Vey, N., Lacombe, C., Solary, E., Birnbaum, D., Bernard, O. A., and Fontenay, M. Mutations of IDH1 and IDH2 genes in early and accelerated phases of myelodysplastic syndromes and MDS/myeloproliferative neoplasms. Leukemia. 2010;24: Lagarde,A., Rouleau, E., Ferrari, A., Noguchi, T., Qiu, J., Briaux, A., Bourdon, V., Remy, V., Gaildrat, P., Adelaide, J., Birnbaum, D., Lidereau, R., Sobol, H., and Olschwang, S. Germline APC mutation spectrum derived from 863 genomic variations identified through a 15-year medical genetics service to French patients with FAP. Journal of Medical Genetics. 2010;47: Lenfant,N., Polanowska, J., Bamps, S., Omi, S., Borg, J. P., and Reboul, J. A genome-wide study of PDZ-domain interactions in C. elegans reveals a high frequency of non-canonical binding. BMC Genomics. 2010;11: Lugari,A., Betzi, S., Decroly, E., Bonnaud, E., Hermant, A., Guillemot, J. C., Debarnot, C., Borg, J. P., Bouvet, M., Canard, B., Morelli, X., and Lecine, P. Molecular mapping of the RNA Cap 2'-O-methyltransferase activation interface between SARS coronavirus nsp10 and nsp16. Journal of 33. Paul,C., Sans, B., Suarez, F., Casassus, P., Barete, S., Lanternier, F., Grandpeix-Guyodo, C., Dubreuil, P., Palmerini, F., Mansfield, C. D., Gineste, P., Moussy, A., Hermine, O., and Lortholary, O. Masitinib for the treatment of systemic and cutaneous mastocytosis with handicap: A phase 2a study. American Journal of Hematology. 2010;85: Pierard,V., Guiguen, A., Colin, L., Wijmeersch, G., Vanhulle, C., Van Driessche, B., Dekoninck, A., Blazkova, J., Cardona, C., Merimi, M., Vierendeel, V., Calomme, C., Nguyen, T. L., Nuttinck, M., Twizere, J. C., Kettmann, R., Portetelle, D., Burny, A., Hirsch, I., Rohr, O., and Van Lint, C. DNA cytosine methylation in the bovine leukemia virus promoter is associated with latency in a lymphoma-derived B-cell line: Potential involvement of direct inhibition of CREB/CREM/ATF transcription factor binding. Journal of Biological Chemistry. 2010;285: Prebet,T., Lhoumeau, A. C., Arnoulet, C., Aulas, A., Marchetto, S., Audebert, S., Puppo, F., Chabannon, C., Sainty, D., Santoni, M. J., Sebbagh, M., Summerour, V., Huon, Y., Shin, W. S., Lee, S. T., Esterni, B., Vey, N., and Borg, J. P. The cell polarity PTK7 receptor acts as a modulator of the chemotherapeutic response in acute myeloid leukaemia and impairs clinical outcome. Blood. 2010;116: Unité de Recherche. Centre de Recherche en Cancérologie de Marseille 15/23

16 36. Reynolds,L.E., Watson, A. R., Baker, M., Jones, T. A., D'Amico, G., Robinson, S. D., Joffre, C., Garrido-Urbani, S., Rodriguez-Manzaneque, J. C., Martino-Echarri, E., Aurrand-Lions, M., Sheer, D., Dagna-Bricarelli, F., Nizetic, D., McCabe, C. J., Turnell, A. S., Kermorgant, S., Imhof, B. A., Adams, R., Fisher, E. M., Tybulewicz, V. L., Hart, I. R., and Hodivala-Dilke, K. M. Tumour angiogenesis is reduced in the Tc1 mouse model of Down's syndrome. Nature. 2010;465: Rocquain,J., Gelsi-Boyer, V., Adelaide, J., Murati, A., Carbuccia, N., Vey, N., Birnbaum, D., Mozziconacci, M. J., and Chaffanet, M. Alteration of cohesin genes in myeloid diseases. American Journal of Hematology. 2010;85: Rocquain,J., Carbuccia, N., Trouplin, V., Raynaud, S., Murati, A., Nezri, M., Tadrist, Z., Olschwang, S., Vey, N., Birnbaum, D., Gelsi-Boyer, V., and Mozziconacci, M. J. Combined mutations of ASXL1, CBL, FLT3, IDH1, IDH2, JAK2, KRAS, NPM1, NRAS, RUNX1, TET2 and WT1 genes in myelodysplastic syndromes and acute myeloid leukemias. BMC Cancer. 2010;10: Sabatier,R., Bouvier, C., de Pinieux, G., Sarran, A., Brenot-Rossi, I., Pedeutour, F., Chetaille, B., Viens, P., Weiller, P. J., and Bertucci, F. Low-grade extraskeletal osteosarcoma of the chest wall: case report and review of literature. BMC Cancer. 2010;10: Sabatier,R., Finetti, P., Cervera, N., Birnbaum, D., and Bertucci, F. DNA microarrays and prediction of clinical outcome in ovarian carcinoma patients. Bulletin du Cancer. 2010;97: Sabatier,R., Adelaide, J., Finetti, P., Ferrari, A., Huiart, L., Sobol, H., Chaffanet, M., Birnbaum, D., and Bertucci, F. BARD1 homozygous deletion, a possible alternative to BRCA1 mutation in basal breast cancer. Genes, Chromosomes and Cancer. 2010;49: Salmi-Smail,C., Fabre, A., Dequiedt, F., Restouin, A., Castellano, R., Garbit, S., Roche, P., Morelli, X., Brunel, J. M., and Collette, Y. Modified cap group suberoylanilide hydroxamic acid histone deacetylase inhibitor derivatives reveal improved selective antileukemic activity. Journal of Medicinal Chemistry. 2010;53: Sedjai,F., Acquaviva, C., Chevrier, V., Chauvin, J. P., Coppin, E., Aouane, A., Coulier, F., Tolun, A., Pierres, M., Birnbaum, D., and Rosnet, O. Control of ciliogenesis by FOR20, a novel centrosome and pericentriolar satellite protein. Journal of Cell Science. 2010;123: Serriari,N.E., Gondois-Rey, F., Guillaume, Y., Remmerswaal, E. B., Pastor, S., Messal, N., Truneh, A., Hirsch, I., van Lier, R. A., and Olive, D. B and T Lymphocyte Attenuator Is Highly Expressed on CMV-Specific T Cells during Infection and Regulates Their Function. Journal of Immunology. 2010;185: Shi,X., Opi, S., Lugari, A., Restouin, A., Coursindel, T., Parrot, I., Perez, J., Madore, E., Zimmermann, P., Corbeil, J., Huang, M., Arold, S. T., Collette, Y., and Morelli, X. Identification and biophysical assessment of the molecular recognition mechanisms between the human haemopoietic cell kinase Src homology domain 3 and ALG-2-interacting protein X. Biochemical Journal. 2010;431: Sircoulomb,F., Bekhouche, I., Finetti, P., Adelaide, J., Ben Hamida, A., Bonansea, J., Raynaud, S., Innocenti, C., Charafe-Jauffret, E., Tarpin, C., Ben Ayed, F., Viens, P., Jacquemier, J., Bertucci, F., Birnbaum, D., and Chaffanet, M. Genome profiling of ERBB2-amplified breast cancers. BMC Cancer. 2010;10: Sokol,H., Georgin-Lavialle, S., Grandpeix-Guyodo, C., Canioni, D., Barete, S., Dubreuil, P., Lortholary, O., Beaugerie, L., and Hermine, O. Gastrointestinal involvement and manifestations in systemic mastocytosis. Inflammatory Bowel Diseases. 2010;16: Taieb,D., Giusiano, S., Sebag, F., Marcy, M., De Micco, C., Palazzo, F. F., Dusetti, N. J., Iovanna, J. L., Henry, J. F., Garcia, S., and Taranger-Charpin, C. Tumor protein p53-induced nuclear protein (TP53INP1) expression in medullary thyroid carcinoma: a molecular guide to the optimal extent of surgery? World Journal of Surgery. 2010;34: Tenan,M., Aurrand-Lions, M., Widmer, V., Alimenti, A., Burkhardt, K., Lazeyras, F., Belkouch, M. C., Hammel, P., Walker, P. R., Duchosal, M. A., Imhof, B. A., and Dietrich, P. Y. Cooperative expression of junctional adhesion molecule-c and -B supports growth and invasion of glioma. Glia. 2010;58: Unité de Recherche. Centre de Recherche en Cancérologie de Marseille 16/23

17 50. Voisset,E., Lopez, S., Chaix, A., Georges, C., Hanssens, K., Prebet, T., Dubreuil, P., and De Sepulveda, P. FES kinases are required for oncogenic FLT3 signaling. Leukemia. 2010;24: Voisset,E., Lopez, S., Chaix, A., Vita, M., George, C., Dubreuil, P., and De Sepulveda, P. FES kinase participates in KIT-ligand induced chemotaxis. Biochemical and Biophysical Research Communications. 2010;393: Yang,Y., Letard, S., Borge, L., Chaix, A., Hanssens, K., Lopez, S., Vita, M., Finetti, P., Birnbaum, D., Bertucci, F., Gomez, S., De Sepulveda, P., and Dubreuil, P. Pediatric mastocytosisassociated KIT extracellular domain mutations exhibit different functional and signaling properties compared with KIT-phosphotransferase domain mutations. Blood. 2010;116: Zaoui,K., Benseddik, K., Daou, P., Salaun, D., and Badache, A. ErbB2 receptor controls microtubule capture by recruiting ACF7 to the plasma membrane of migrating cells. Proceedings of the National Academy of Sciences of the United States of America. 2010;107: Arcangeli,M.L., Frontera, V., Bardin, F., Obrados, E., Adams, S., Chabannon, C., Schiff, C., Mancini, S. J., Adams, R. H., and Aurrand-Lions, M. JAM-B regulates maintenance of hematopoietic stem cells in the bone marrow. Blood. 2011;118: Baron Gaillard,C.L., Pallesi-Pocachard, E., Massey-Harroche, D., Richard, F., Arsanto, J. P., Chauvin, J. P., Lecine, P., Kramer, H., Borg, J. P., and Le Bivic, A. Hook2 is involved in the morphogenesis of the primary cilium. Molecular Biology of the Cell. 2011;22: Bekhouche,I., Finetti, P., Adelaide, J., Ferrari, A., Tarpin, C., Charafe-Jauffret, E., Charpin, C., Houvenaeghel, G., Jacquemier, J., Bidaut, G., Birnbaum, D., Viens, P., Chaffanet, M., and Bertucci, F. High-resolution comparative genomic hybridization of inflammatory breast cancer and identification of candidate genes. PLoS ONE. 2011;6:e Bertucci,F., Borie, N., Roche, H., Bachelot, T., Le Doussal, J. M., MacGrogan, G., Debono, S., Martinec, A., Treilleux, I., Finetti, P., Esterni, B., Extra, J. M., Geneve, J., Hermitte, F., Chabannon, C., Jacquemier, J., Martin, A. L., Longy, M., Maraninchi, D., Fert, V., Birnbaum, D., and Viens, P. Gene expression profile predicts outcome after anthracycline-based adjuvant chemotherapy in early breast cancer. Breast Cancer Research and Treatment. 2011;127: Birnbaum,D.J., Birnbaum, D., and Bertucci, F. Endometriosis-associated ovarian carcinomas. New England Journal of Medicine. 2011;364: Birnbaum,D.J., Adelaide, J., Mamessier, E., Finetti, P., Lagarde, A., Monges, G., Viret, F., Goncalves, A., Turrini, O., Delpero, J. R., Iovanna, J., Giovannini, M., Birnbaum, D., and Chaffanet, M. Genome profiling of pancreatic adenocarcinoma. Genes, Chromosomes and Cancer. 2011;50: Bozzano,F., Picciotto, A., Costa, P., Marras, F., Fazio, V., Hirsch, I., Olive, D., Moretta, L., and De Maria, A. Activating NK cell receptor expression/function (NKp30,NKp46,DNAM-1) during chronic viraemic HCV infection is associated with the outcome of combined treatment. European Journal of Immunology. 2011;41: Brecqueville,M., Cervera, N., Rey, J., Adelaide, J., Carbuccia, N., Chaffanet, M., Mozziconacci, M. J., Vey, N., Birnbaum, D., Gelsi-Boyer, V., and Murati, A. Mutations and deletions of the SUZ12 polycomb gene in myeloproliferative neoplasms. Blood Cancer Journal. 2011;1:e Brecqueville,M., Cervera, N., Gelsi-Boyer, V., Murati, A., Adelaide, J., Chaffanet, M., Rey, J., Vey, N., Mozziconacci, M. J., and Birnbaum, D. Rare mutations in DNMT3A in myeloproliferative neoplasms and myelodysplastic syndromes. Blood Cancer Journal. 2011;1:e Cadot,P., Hensel, P., Bensignor, E., Hadjaje, C., Marignac, G., Beco, L., Fontaine, J., Jamet, J. F., Georgescu, G., Campbell, K., Cannon, A., Osborn, S. C., Messinger, L., Gogny-Goubert, M., Dubreuil, P., Moussy, A., and Hermine, O. Masitinib decreases signs of canine atopic dermatitis: a multicentre, randomized, double-blind, placebo-controlled phase 3 trial. Veterinary Dermatology. 2011;22: Unité de Recherche. Centre de Recherche en Cancérologie de Marseille 17/23

18 64. Carcopino,X., Bolger, N., Henry, M., Mancini, J., Boubli, L., Olive, D., Cleary, S., Prendiville, W., and Tamalet, C. Evaluation of type-specific HPV persistence and high-risk HPV viral load quantitation in HPV positive women under 30 with normal cervical cytology. Journal of Medical Virology. 2011;83: Chaib,H., Prebet, T., Vey, N., and Collette, Y. Histone méthyltransférases:une nouvelle classe de cibles thérapeutiques dans le traitement du cancer? M/S Medecine Sciences. 2011;27: Chaix,A., Lopez, S., Voisset, E., Gros, L., Dubreuil, P., and De Sepulveda, P. Mechanisms of STAT proteins activation by oncogenic kit mutants in neoplastic mast cells. Journal of Biological Chemistry. 2011;286: Feracci,M., Pimentel, C., Bornet, O., Roche, P., Salaun, D., Badache, A., and Guerlesquin, F. MEMO associated with an ErbB2 receptor phosphopeptide reveals a new phosphotyrosine motif. FEBS Letters. 2011;585: Fournier,G., Cabaud, O., Josselin, E., Chaix, A., Adelaide, J., Isnardon, D., Restouin, A., Castellano, R., Dubreuil, P., Chaffanet, M., Birnbaum, D., and Lopez, M. Loss of AF6/afadin, a marker of poor outcome in breast cancer, induces cell migration, invasiveness and tumor growth. Oncogene. 2011;30: Franceschi,C., Collignon, A., Isnardon, D., Benkoel, L., Verine, A., Silvy, F., Bernard, J. P., Lombardo, D., Beraud, E., Olive, D., and Mas, E. A novel tumor-associated pancreatic glycoprotein is internalized by human dendritic cells and induces their maturation. Journal of Immunology. 2011;186: Frontera,V., Arcangeli, M. L., Zimmerli, C., Bardin, F., Obrados, E., Audebert, S., Bajenoff, M., Borg, J. P., and Aurrand-Lions, M. Cutting Edge: JAM-C Controls Homeostatic Chemokine Secretion in Lymph Node Fibroblastic Reticular Cells Expressing Thrombomodulin. Journal of Immunology. 2011;187: Georgescu,S.P., Aronovitz, M. J., Iovanna, J. L., Patten, R. D., Kyriakis, J. M., and Goruppi, S. Decreased metalloprotease 9 induction, cardiac fibrosis, and higher autophagy after pressure overload in mice lacking the transcriptional regulator p8. American Journal of Physiology-Cell Physiology. 2011;301:C1046-C Georgin-Lavialle,S., Lhermitte, L., Baude, C., Barete, S., Bruneau, J., Launay, J. M., Chandesris, M. O., Hanssens, K., de Gennes, C., Damaj, G., Lanternier, F., Hamidou, M., Lortholary, O., Dubreuil, P., Feger, F., Lepelletier, Y., and Hermine, O. Blood CD34-c-Kit+ cell rate correlates with aggressive forms of systemic mastocytosis and behaves like a mast cell precursor. Blood. 2011;118: Ginestier,C., Sircoulomb, F., Charafe-Jauffret, E., Chaffanet, M., and Birnbaum, D. ZNF703: un nouvel oncogène du cancer du sein. M/S Medecine Sciences. 2011;27: Ginestier,C., Charafe-Jauffret, E., and Birnbaum, D. Breast tumor microenvironment: In the eye of the cytokine storm. Cell Cycle. 2011;10: Goncalves,A., Finetti, P., Sabatier, R., Gilabert, M., Adelaide, J., Borg, J. P., Chaffanet, M., Viens, P., Birnbaum, D., and Bertucci, F. Poly(ADP-ribose) polymerase-1 mrna expression in human breast cancer: a meta-analysis. Breast Cancer Research and Treatment. 2011;127: Jacquemier,J., Boher, J. M., Roche, H., Esterni, B., Serin, D., Kerbrat, P., Andre, F., Finetti, P., Charafe-Jauffret, E., Martin, A. L., Campone, M., Viens, P., Birnbaum, D., Penault-Llorca, F., and Bertucci, F. Protein expression, survival and docetaxel benefit in node-positive breast cancer treated with adjuvant chemotherapy in the FNC. Breast Cancer Research. 2011;13:R Letessier,A., Birnbaum, D., Debatisse, M., and Chaffanet, M. La pauvreté en sites d'initiation de la réplication rend-elle fragile certaines régions du génome? M/S Medecine Sciences. 2011;27: Unité de Recherche. Centre de Recherche en Cancérologie de Marseille 18/23

19 78. Lhoumeau,A.C., Puppo, F., Prebet, T., Kodjabachian, L., and Borg, J. P. PTK7: A cell polarity receptor with multiple facets. Cell Cycle. 2011;10: Lugari,A., Breuer, S., Coursindel, T., Opi, S., Restouin, A., Shi, X., Nazabal, A., Torbett, B. E., Martinez, J., Collette, Y., Parrot, I., Arold, S. T., and Morelli, X. A specific protein disorder catalyzer of HIV-1 Nef. Bioorganic and Medicinal Chemistry. 2011;19: Maddugoda,M.P., Stefani, C., Gonzalez-Rodriguez, D., Saarikangas, J., Torrino, S., Janel, S., Munro, P., Doye, A., Prodon, F., Aurrand-Lions, M., Goossens, P. L., Lafont, F., Bassereau, P., Lappalainen, P., Brochard, F., and Lemichez, E. camp Signaling by Anthrax Edema Toxin Induces Transendothelial Cell Tunnels, which Are Resealed by MIM via Arp2/3-Driven Actin Polymerization. Cell Host Microbe. 2011;10: Mamessier,E., Sylvain, A., Thibult, M. L., Houvenaeghel, G., Jacquemier, J., Castellano, R., Goncalves, A., Andre, P., Romagne, F., Thibault, G., Viens, P., Birnbaum, D., Bertucci, F., Moretta, A., and Olive, D. Human breast cancer cells enhance self tolerance by promoting evasion from NK cell antitumor immunity. Journal of Clinical Investigation. 2011;121: Mamessier,E., Sylvain, A., Bertucci, F., Castellano, R., Finetti, P., Houvenaeghel, G., Charaffe- Jaufret, E., Birnbaum, D., Moretta, A., and Olive, D. Human breast tumor cells induce selftolerance mechanisms to avoid NKG2D-mediated and DNAM-mediated NK-cells recognition. Cancer Research. 2011;71: Messal,N., Mamessier, E., Sylvain, A., Celis-Gutierrez, J., Thibult, M. L., Chetaille, B., Firaguay, G., Pastor, S., Guillaume, Y., Wang, Q., Hirsch, I., Nunes, J. A., and Olive, D. Differential role for CD277 as co-regulator of the immune signal in T and NK cells. European Journal of Immunology. 2011;41: Messal,N., Serriari, N. E., Pastor, S., Nunes, J. A., and Olive, D. PD-L2 is expressed on activated human T cells and regulates their function. Molecular Immunology. 2011;48: Olive,D., le Thi, S., Xerri, L., Hirsch, I., and Nunes, J. A. Rôle de CTLA-4 dans la cosignalisation négative du système immunitaire. M/S Medecine Sciences. 2011;27: Piette,F., Belmin, J., Vincent, H., Schmidt, N., Pariel, S., Verny, M., Marquis, C., Mely, J., Hugonot-Diener, L., Kinet, J. P., Dubreuil, P., Moussy, A., and Hermine, O. Masitinib as an adjunct therapy for mild-to-moderate Alzheimer's disease: a randomised, placebo-controlled phase 2 trial. Alzheimer's Research and Therapy. 2011;3: Prebet,T., Etienne, A., Devillier, R., Romeo, E., Charbonnier, A., D'incan, E., Esterni, B., Arnoulet, C., Blaise, D., and Vey, N. Improved outcome of patients with low- and intermediate-risk cytogenetics acute myeloid leukemia (AML) in first relapse with gemtuzumab and cytarabine versus cytarabine: results of a retrospective comparative study. Cancer. 2011;117: Prebet,T., Gore, S. D., Esterni, B., Gardin, C., Itzykson, R., Thepot, S., Dreyfus, F., Rauzy, O. B., Recher, C., Ades, L., Quesnel, B., Beach, C. L., Fenaux, P., and Vey, N. Outcome of high-risk myelodysplastic syndrome after azacitidine treatment failure. Journal of Clinical Oncology. 2011;29: Prebet,T. and Vey, N. Vorinostat in acute myeloid leukemia and myelodysplastic syndromes. Expert Opinion on Investigational Drugs. 2011;20: Puppo,F., Thome, V., Lhoumeau, A. C., Cibois, M., Gangar, A., Lembo, F., Belotti, E., Marchetto, S., Lecine, P., Prebet, T., Sebbagh, M., Shin, W. S., Lee, S. T., Kodjabachian, L., and Borg, J. P. Protein tyrosine kinase 7 has a conserved role in Wnt/beta-catenin canonical signalling. EMBO Report. 2011;12: Qiu,J., Hutter, P., Rahner, N., Patton, S., and Olschwang, S. The educational role of external quality assessment in genetic testing: a 7-year experience of The European Molecular Genetics Quality Network (EMQN) in Lynch syndrome. Human Mutation. 2011;32: Unité de Recherche. Centre de Recherche en Cancérologie de Marseille 19/23

20 92. Qiu,J., Compagnone, M., Laibe, S., Lagarde, A., Goncalves, A., Turrini, O., Xerri, L., Monges, G., and Olschwang, S. BRAF p.val600glu (V600E) somatic mutation is mainly associated with MSS phenotype in metastatic colorectal cancer. Cancer Genomics and Proteomics. 2011;8: Sabatier,R., Finetti, P., Mamessier, E., Raynaud, S., Cervera, N., Lambaudie, E., Jacquemier, J., Viens, P., Birnbaum, D., and Bertucci, F. Kinome expression profiling and prognosis of basal breast cancers. Molecular Cancer. 2011;10: Sabatier,R., Finetti, P., Adelaide, J., Guille, A., Borg, J. P., Chaffanet, M., Lane, L., Birnbaum, D., and Bertucci, F. Down-regulation of ECRG4, a candidate tumor suppressor gene, in human breast cancer. PLoS ONE. 2011;6:e Sabatier,R., Finetti, P., Bonensea, J., Jacquemier, J., Adelaide, J., Lambaudie, E., Viens, P., Birnbaum, D., and Bertucci, F. A seven-gene prognostic model for platinum-treated ovarian carcinomas. British Journal of Cancer. 2011;105: Sabatier,R., Jacquemier, J., Bertucci, F., Esterni, B., Finetti, P., Azario, F., Birnbaum, D., Viens, P., Goncalves, A., and Extra, J. M. Peritumoural vascular invasion: A major determinant of triplenegative breast cancer outcome. European Journal of Cancer. 2011;47: Sabatier,R., Finetti, P., Cervera, N., Tallet, A., Benchalal, M., Houvenaeghel, G., Jacquemier, J., Birnbaum, D., and Bertucci, F. Gene Expression Profiling and its Utility in Prediction of Local Relapse after Breast-conserving Therapy in Early Breast Cancer. Cancer Genomics and Proteomics. 2011;8: Sanchez,C.J., Le Treut T., Boehrer, A., Knoblauch, B., Imbert, J., Olive, D., and Costello, R. T. Natural killer cells and malignant haemopathies: a model for the interaction of cancer with innate immunity. Cancer Immunology, Immunotherapy. 2011;60: Sebbagh,M., Olschwang, S., Santoni, M. J., and Borg, J. P. The LKB1 complex-ampk pathway: the tree that hides the forest. Familial Cancer. 2011;10: Sircoulomb,F., Nicolas, N., Ferrari, A., Finetti, P., Bekhouche, I., Rousselet, E., Lonigro, A., Adelaide, J., Baudelet, E., Esteyries, S., Wicinski, J., Audebert, S., Charafe-Jauffret, E., Jacquemier, J., Lopez, M., Borg, J. P., Sotiriou, C., Popovici, C., Bertucci, F., Birnbaum, D., Chaffanet, M., and Ginestier, C. ZNF703 gene amplification at 8p12 specifies luminal B breast cancer. EMBO Molecular Medicine. 2011;3: Spicuglia,S., Vincent-Fabert, C., Benoukraf, T., Tiberi, G., Saurin, A. J., Zacarias-Cabeza, J., Grimwade, D., Mills, K., Calmels, B., Bertucci, F., Sieweke, M., Ferrier, P., and Duprez, E. Characterisation of Genome-Wide PLZF/RARA Target Genes. PLoS ONE. 2011;6:e Trejbalova,K., Blazkova, J., Matouskova, M., Kucerova, D., Pecnova, L., Vernerova, Z., Heracek, J., Hirsch, I., and Hejnar, J. Epigenetic regulation of transcription and splicing of syncytins, fusogenic glycoproteins of retroviral origin. Nucleic Acids Research. 2011;39: Zhao,X.W., van Beek, E. M., Schornagel, K., Van der Maaden, H., Van Houdt, M., Otten, M. A., Finetti, P., Van Egmond, M., Matozaki, T., Kraal, G., Birnbaum, D., van Elsas, A., Kuijpers, T. W., Bertucci, F., and van den Berg, T. K. CD47-signal regulatory protein-alpha (SIRPalpha) interactions form a barrier for antibody-mediated tumor cell destruction. Proceedings of the National Academy of Sciences of the United States of America. 2011;108: Gillibert-Duplantier J, Duthey B, Sisirak V, Salaün D, Gargi T, Trédan O, Finetti P, Bertucci F, Birnbaum D, Bendriss-Vermare N, Badache A. Gene expression profiling identifies sst2 as an effector of ErbB2-driven breast carcinoma cell motility, associated with metastasis. Oncogene Nov 21. doi: /onc Unité de Recherche. Centre de Recherche en Cancérologie de Marseille 20/23